US2022064720A1PendingUtilityA1

Isolation of target nucleic acids

Assignee: GENETICS RES LLC D/B/A ZS GENETICS INCPriority: Jun 13, 2017Filed: Oct 11, 2021Published: Mar 3, 2022
Est. expiryJun 13, 2037(~10.9 yrs left)· nominal 20-yr term from priority
Inventors:William Glover
C12Q 1/6806C12Q 1/6811C12Q 1/6827C12Q 1/6846C12Q 2521/319C12N 2310/334C12Q 1/6853C12Q 1/6876C12N 2310/335C12Q 1/682C12N 2310/333
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods of isolating a target nucleic acid in a sample. A primer is hybridized to the target. A polymerase and modified nucleotide resistant to nuclease degradation are used to extend the primer to create a modified polynucleotide. The sample is exposed to a nuclease, thereby isolating the modified polynucleotide. Optionally, the target nucleic acid may be further protected by binding a protein in a sequence specific manner to one end of the target nucleic acid to create a protected target nucleic acid resistant to nuclease degradation. Thus, after exposing the sample to a nuclease, the modified polynucleotide and protected target nucleic acid are isolated.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for isolating a target nucleic acid, the method comprising:
 hybridizing at least one primer to a target nucleic acid in a sample;   extending the primer using a polymerase and modified nucleotides that are resistant to nuclease degradation to create a modified polynucleotide;   exposing the sample to a nuclease; and   isolating the modified polynucleotides.   
     
     
         2 . The method of  claim 1 , wherein the modified nucleotides comprise modified nucleotide triphosphates. 
     
     
         3 . The method of  claim 2 , wherein the modified nucleotide triphosphates comprise alpha-phosphorothioate nucleotide triphosphates, morpholino triphosphates, peptide nucleic acids, peptide nucleic acid analogs, or sugar modified nucleotide triphosphates. 
     
     
         4 . The method of  claim 3 , wherein the modified nucleotide triphosphates are selected from the group consisting of 2′-Deoxycytidine-5′-O-(1-Thiotriphosphate), 2′-O-methyl modified nucleotide triphosphate, 2′-fluoro modified nucleotide, 2′-O-Methyladenosine-5′-Triphosphate, 2′-O-Methylcytidine-5′-Triphosphate, 2′-O-Methylguanosine-5′-Triphosphate, 2′-O-Methyluridine-5′-Triphosphate, 2′-O-Methylinosine-5′-Triphosphate, 2′-O-Methyl-2-aminoadenosine-5′-Triphosphate, 2′-O-Methylpseudouridine-5′-Triphosphate, 2′-O-Methyl-5-methyluridine-5′-Triphosphate, 2′-O-Methyl-N6-Methyladenosine-5′-Triphosphate, 2′-Fluoro-2′-deoxyadenosine-5′-Triphosphate, 2′-Fluoro-2′-deoxycytidine-5′-Triphosphate, 2′-Fluoro-2′-deoxyguanosine-5′-Triphosphate, 2′-Fluoro-2′-deoxyuridine-5′-Triphosphate, and 2′-Fluoro-thymidine-5′-Triphosphate. 
     
     
         5 . The method of  claim 1 , wherein natural nucleotides are used in combination with modified nucleotides. 
     
     
         6 . The method of  claim 1 , wherein two primers are used for hybridization. 
     
     
         7 . The method of  claim 6 , further comprising amplification of the modified polynucleotide. 
     
     
         8 . The method of  claim 2 , further comprising dephosphorylating the target nucleic acid using a phosphatase. 
     
     
         9 . The method of  claim 1 , wherein the nuclease comprises an exonuclease. 
     
     
         10 . The method of  claim 1 , further comprising detecting the target nucleic acid. 
     
     
         11 . The method of  claim 10 , wherein the detecting step comprises using hybridization, spectrophotometry, sequencing, electrophoresis, amplification, fluorescence detection, chromatography, DNA staining, or microscopy. 
     
     
         12 . The method of  claim 1 , wherein the sample is a blood sample, serum sample, plasma sample, urine sample, saliva sample, semen sample, feces sample, phlegm sample, or liquid biopsy. 
     
     
         13 . A method for isolating a target nucleic acid, the method comprising:
 hybridizing at least one primer to a first end of a target nucleic acid in a sample;   extending the primer using a polymerase and modified nucleotides that are resistant to nuclease degradation to create a modified polynucleotide;   binding at least one protein to a second end of the target nucleic acid in a sequence-specific manner to create protected target nucleic acid resistant to nuclease degradation;   exposing the sample to a nuclease; and   isolating the modified polynucleotides and protected target nucleic acid.   
     
     
         14 . The method of  claim 13 , wherein the modified nucleotides comprise modified nucleotide triphosphates. 
     
     
         15 . The method of  claim 13 , wherein natural nucleotides are used in combination with modified nucleotides. 
     
     
         16 . The method of  claim 14 , wherein the modified nucleotide triphosphates comprise alpha-phosphorothioate nucleotide triphosphates, morpholino triphosphates, peptide nucleic acids, peptide nucleic acid analogs, or sugar modified nucleotide triphosphates. 
     
     
         17 . The method of  claim 16 , wherein the modified nucleotide triphosphates are selected from the group consisting of 2′-Deoxycytidine-5′-O-(1-Thiotriphosphate), 2′-O-methyl modified nucleotide triphosphate, 2′-fluoro modified nucleotide, 2′-O-Methyladenosine-5′-Triphosphate, 2′-O-Methylcytidine-5′-Triphosphate, 2′-O-Methylguanosine-5′-Triphosphate, 2′-O-Methyluridine-5′-Triphosphate, 2′-O-Methylinosine-5′-Triphosphate, 2′-O-Methyl-2-aminoadenosine-5′-Triphosphate, 2′-O-Methylpseudouridine-5′-Triphosphate, 2′-O-Methyl-5-methyluridine-5′-Triphosphate, 2′-O-Methyl-N6-Methyladenosine-5′-Triphosphate, 2′-Fluoro-2′-deoxyadenosine-5′-Triphosphate, 2′-Fluoro-2′-deoxycytidine-5′-Triphosphate, 2′-Fluoro-2′-deoxyguanosine-5′-Triphosphate, 2′-Fluoro-2′-deoxyuridine-5′-Triphosphate, and 2′-Fluoro-thymidine-5′-Triphosphate. 
     
     
         18 . The method of  claim 14 , wherein the at least one protein comprises a Cas endonuclease complexed with a guide RNA that targets the Cas endonuclease to a region of the target nucleic acid. 
     
     
         19 . The method of  claim 18 , wherein the Cas endonuclease is catalytically inactive. 
     
     
         20 . The method of  claim 14 , wherein the nuclease comprises an exonuclease. 
     
     
         21 . The method of  claim 14 , further comprising detecting the target nucleic acid. 
     
     
         22 . The method of  claim 21 , wherein the detecting step comprises using hybridization, spectrophotometry, sequencing, electrophoresis, amplification, fluorescence detection, chromatography, DNA staining, or microscopy. 
     
     
         23 . The method of  claim 14 , wherein the sample is a blood sample, serum sample, plasma sample, urine sample, saliva sample, semen sample, feces sample, phlegm sample, or liquid biopsy.

Join the waitlist — get patent alerts

Track US2022064720A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.